Technical Analysis for BPMC - Blueprint Medicines Corporation

Grade Last Price % Change Price Change
grade D 74.63 -1.44% -1.09
BPMC closed down 1.44 percent on Thursday, August 6, 2020, on 62 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Flat
Historical BPMC trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Crossed Above 50 DMA Bullish -1.44%
180 Bullish Setup Bullish Swing Setup -1.44%
Fell Below 50 DMA Bearish 1.45%
180 Bearish Setup Bearish Swing Setup 1.45%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.45%
NR7 Range Contraction 1.45%
Inside Day Range Contraction 1.45%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.
Biopharmaceutical Cancer Cell Biology Tyrosine Kinase Receptors Cell Signaling Protein Kinase Inhibitor Rare Genetic Diseases Tyrosine Kinase Mastocytosis Fibroblast Growth Factor Receptor Gastrointestinal Stromal Tumor Myeloproliferative Neoplasm Rare Genetic Disease Systemic Mastocytosis

Is BPMC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 91.25
52 Week Low 43.29
Average Volume 530,812
200-Day Moving Average 69.71
50-Day Moving Average 75.40
20-Day Moving Average 76.29
10-Day Moving Average 74.45
Average True Range 2.87
ADX 19.41
+DI 12.54
-DI 18.51
Chandelier Exit (Long, 3 ATRs ) 73.72
Chandelier Exit (Short, 3 ATRs ) 80.44
Upper Bollinger Band 80.54
Lower Bollinger Band 72.03
Percent B (%b) 0.31
BandWidth 11.16
MACD Line -0.42
MACD Signal Line -0.07
MACD Histogram -0.3478
Fundamentals Value
Market Cap 2.92 Billion
Num Shares 39.1 Million
EPS -3.12
Price-to-Earnings (P/E) Ratio -23.92
Price-to-Sales 103.31
Price-to-Book 7.06
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 78.70
Resistance 3 (R3) 78.72 77.39 78.02
Resistance 2 (R2) 77.39 76.36 77.38 77.79
Resistance 1 (R1) 76.01 75.72 75.35 75.99 77.57
Pivot Point 74.68 74.68 74.35 74.67 74.68
Support 1 (S1) 73.30 73.64 72.63 73.27 71.69
Support 2 (S2) 71.97 73.00 71.95 71.47
Support 3 (S3) 70.59 71.97 71.24
Support 4 (S4) 70.56